Recent Advances of Inflammasomes in Central Nervous System Disorders
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biology".
Deadline for manuscript submissions: closed (20 November 2021) | Viewed by 326
Special Issue Editors
Interests: ischemia; traumatic brain injury; chronic traumatic encephalopathy; spinal cord injury; ginsenosides
Special Issue Information
Dear Colleagues,
Since being discovered in 2002, inflammasomes have been spotlighted for their crucial roles in the innate immune system. Inflammasomes are cytosolic multiprotein oligomers and are activated by exogenous and endogenous stimuli. Activation of inflammasomes promotes the secretion of pro-inflammatory cytokines interleukin 1β (IL-1β) and interleukin 18 (IL-18), triggers innate immune response and, finally, the apoptosis and pyroptosis of cells.
In the central nervous system (CNS), inflammasomes are expressed in the immunocompetent microglia, infiltrating myeloid cells, astrocyte and neuron. The activation of inflammasomes is observed upon infection, traumatic injury, stroke and neurodegenerative disease in the CNS. Besides these CNS disorders, inflammasomes activation is found to be involved in the development and aging of brain. Recent evidence indicates that interception of inflammasomes activation attenuates the progression of multiple sclerosis and Alzheimer's disease. In traumatic brain injury and spinal cord injury, reduced inflammasomes activation leads to functional improvement. This evidence indicates the possibility of inflammasomes as a potential therapy target for CNS diseases.
This Special Issue will focus on the recent advances of inflammasomes in the central nerve system disorders, including traumatic injury, infection, stroke and neurodegenerative disease. We invite investigators to contribute high-quality original research and review articles focused on these aspects to explore the possible therapeutic role of inflammasomes in CNS disorders.
Prof. Masahiro Sakanaka
Dr. Pengxiang Zhu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Inflammasomes
- NLRP1, NLRP3, ASC
- Traumatic Brain Injury
- Spinal Cord Injury
- Multiple sclerosis
- Alzheimer's disease
